Acute Kidney InjuryVINKONCT07643597
Volume Removal Intolerance During Net Ultrafiltration in Acute Kidney Injury Patients
An observational study of Acute Kidney Injury and Fluid Overload, run by Hospital Las Higueras at 10 sites in 7 countries.
Trial summary
Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Kidney Injury, Fluid Overload, Fluid Overload in Dialysis Patients
- How many people
- 128 participants
- Where
- 10 sitesin 7 countries
- Study dates
- 6 Jul 2026to 1 Dec 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Adult critically ill patients admitted to participating intensive care units with acute kidney injury requiring continuous renal replacement therapy and prescribed net ultrafiltration as part of routine clinical care.
Who may be able to join
- Age ≥18 years
- Admission to an Intensive Care Unit
- Acute kidney injury according to KDIGO criteria
- Prescription of continuous renal replacement therapy (CRRT) with net ultrafiltration
- Clinical stability considered sufficient to initiate net ultrafiltration according to the treating clinical team
Who cannot join
- Chronic kidney replacement therapy prior to ICU admission
- Pregnancy
- Limitation of therapeutic effort or goals-of-care decisions at admission or during the observation period
- Inability to perform hemodynamic or perfusion assessment
- Extracorporeal membrane oxygenation (ECMO)
- Refusal to participate in the study
Trial locations and contacts
10 sites in 7 countries. Contact the study team or a site near you to ask about taking part.
Cristian Pedreros-Rosales, MD contact
10 sites in 7 countries
Chile4 sites, 4 recruiting
- Not yet recruiting
Hospital Clínico Regional de Concepción
Concepción
Marcos Hernandez, MD, +56976685604, md.hernandezdiaz@gmail.com
- Not yet recruiting
Complejo Asistencial Dr. Victor Ríos Ruiz
Los Ángeles
Carolina Carrasco, MD, +56975583888, carolina.carrascoa@gmail.com
- Not yet recruiting
Hospital Clínico Dra. Eloísa Díaz Insunza de La Florida
Santiago
Eduardo Chinchón, MD, +56994514773, doctorchinchon@gmail.com
- Recruiting
Hospital Las Higueras de Talcahuano
Talcahuano
Gonzalo Ramírez-Guerrero, MD, +56981746173, ramirezguerrero.g@gmail.com
Cristian Pedreros-Rosales, MD, cpedreros@me.com
Brazil1 site, 1 recruiting
- Not yet recruiting
Hospital Cárdio Pulmonar
Salvador
Maria Gabriela Guimarães, MD, +5571982121211, Gabrielaguimar@hotmail.com
Colombia1 site, 1 recruiting
- Recruiting
Hospital Universitario San José de Popayán
Popayán
David Ballesteros, MD, +573105542506, david.ballesteros.c@gmail.com
Ecuador1 site, 1 recruiting
- Not yet recruiting
Hospital General Enrique Garces
Quito
Darío Jiménez, MD, +593992773176, dxjimenezmd@gmail.com
Italy1 site, 1 recruiting
- Not yet recruiting
Ospedale San Bortolo
Vicenza
Matteo Marcello, MD, +393925743247, matteo.marcello92@gmail.com
Mexico1 site, 1 recruiting
- Recruiting
Hospital General de Mexico
Mexico City
Pablo Galindo, MD, +525551564682, drgalindo@nefrologoscdmx.com
Sandra Ávila, MD, +524778808890, sandrapav@hotmail.es
Peru1 site, 1 recruiting
- Not yet recruiting
Hospital Nacional Cayetano Heredia
Lima
Raúl Valenzuela, MD, +51999308278, raul.valenzuela.cordova@gmail.com
About this study
Acute kidney injury (AKI) is common in critically ill patients and is frequently associated with fluid overload, which can worsen clinical outcomes. Continuous renal replacement therapy (CRRT) allows fluid removal through net ultrafiltration (UFNET), but some patients develop hemodynamic instability or signs of poor tissue perfusion during this process.
The purpose of this prospective observational study is to evaluate tolerance to net ultrafiltration in critically ill patients with AKI receiving CRRT. The study will assess clinical, hemodynamic, ultrasound, perfusion, and biochemical parameters before and during fluid removal to identify factors associated with ultrafiltration intolerance.
The investigators hypothesize that alterations in hemodynamic, perfusion, and congestion-related parameters can identify patients at increased risk of ultrafiltration intolerance before the development of overt hypotension. The results may help improve individualized fluid removal strategies and optimize the safety of CRRT in critically ill patients.
Read the detailed description
Fluid overload is a frequent and clinically relevant complication in critically ill patients with acute kidney injury (AKI). In this setting, continuous renal replacement therapy (CRRT) is frequently used not only for solute control but also as a strategy for controlled fluid removal through net ultrafiltration (UFNET). Although UFNET is central to de-resuscitation, the individual tolerance to fluid removal is highly variable and is not fully captured by blood pressure monitoring alone.
The concept of ultrafiltration intolerance remains poorly standardized. In clinical practice, intolerance is often recognized only after overt hemodynamic instability occurs, such as hypotension, escalation of vasoactive support, or interruption of fluid removal. However, reductions in cardiac output, impaired tissue perfusion, or worsening venous congestion may precede overt hypotension. Therefore, a multiparametric assessment may allow earlier identification of patients at risk.
This is a prospective, observational, analytical study in critically ill adult patients with AKI receiving CRRT with prescribed UFNET. The study does not assign or modify therapeutic interventions. CRRT modality, anticoagulation strategy, UFNET prescription, vasopressor management, fluid administration, and all other clinical decisions will remain under the responsibility of the treating clinical team according to routine care.
The study will characterize the physiological response to UFNET using a structured multiparametric monitoring approach. Recorded domains will include conventional macrohemodynamic variables, vasoactive support, selected advanced hemodynamic variables when available, focused cardiac ultrasound, venous congestion assessment, peripheral perfusion parameters, fluid balance variables, and selected biochemical markers. Functional hemodynamic maneuvers may be performed when feasible and clinically safe.
Data will be collected prospectively using a standardized case report form. Variables will be recorded at predefined time points before and during the early phase of UFNET, with additional off-schedule recordings if clinical signs compatible with intolerance occur. Source data will be obtained from the electronic or paper medical record, bedside monitoring systems, CRRT prescription and treatment records, laboratory results, and ultrasound assessments performed as part of clinical evaluation.
A data dictionary will define each variable, including its source, units, coding, and expected physiological range when applicable. Data quality procedures will include review of completeness, range checks, consistency checks between related variables, and verification of clinically implausible values against source records. The research team will periodically review entered data to identify missing, inconsistent, or out-of-range values.
Data will be anonymized before analysis. No directly identifiable patient information will be stored in the final analytical database. Access to the study database will be restricted to authorized study investigators. Data will be stored using password-protected institutional or investigator-controlled systems according to local confidentiality and ethical requirements.
The planned sample size is 128 participants, including an estimated analytical sample of 116 participants and an approximate 10% over-recruitment to account for incomplete data, missing assessments, or inability to definitively adjudicate the outcome. The sample size was based on an analytical case-control approach aimed at identifying factors associated with ultrafiltration intolerance.
Missing data will be evaluated before statistical analysis. Variables with substantial missingness may be excluded from inferential analyses. For variables with acceptable levels of missingness, available-case analysis will be performed. The extent and pattern of missing data will be reported.
Statistical analysis will include descriptive statistics, comparison between patients who develop ultrafiltration intolerance and those who do not, and exploratory modeling to identify factors independently associated with intolerance. Continuous variables will be summarized using median and interquartile range or mean and standard deviation, as appropriate. Categorical variables will be summarized as frequencies and percentages. Group comparisons will be performed using appropriate parametric or non-parametric tests according to data distribution. Multivariable logistic regression may be used to explore independent predictors, with covariate selection based on clinical relevance and number of events.
The overall objective of this study is to improve the characterization of ultrafiltration intolerance during CRRT and to generate evidence that may support individualized, physiology-guided fluid removal strategies in critically ill patients with AKI.
- Conditions
- Acute Kidney Injury, Fluid Overload, Fluid Overload in Dialysis Patients, Critical Illness, Renal Replacement Therapy for Acute Kidney Injury in ICU
- Keywords
- Net Ultrafiltration, Continuous Renal Replacement Therapy, Fluid Removal, Ultrafiltration Intolerance, Tissue Hypoperfusion, Fluid Overload, VExUS, Point-of-Care Ultrasound
- Medical subject headings
- Acute Kidney Injury, Edema, Critical Illness
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| AKI Patients Receiving CRRT With Net Ultrafiltration | Adult critically ill patients with acute kidney injury receiving continuous renal replacement therapy with prescribed net ultrafiltration. Participants will be prospectively evaluated using a multiparametric monitoring strategy including clinical, hemodynamic, ultrasound, perfusion, and biochemical assessments. Patients will subsequently be classified according to the development or absence of ultrafiltration intolerance during the observation period. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Development of Ultrafiltration Intolerance
Proportion of patients who develop ultrafiltration intolerance according to the protocol-defined composite criteria, including hypotension, increased vasopressor requirements, worsening peripheral perfusion, tissue hypoperfusion, or reduction/interruption of ultrafiltration due to instability.
Measured: From UFNET initiation (T0) to 24 hours after initiation of net ultrafiltration
Secondary outcomes (11)
Incidence of Ultrafiltration Intolerance
Percentage of participants who develop ultrafiltration intolerance during the observation period.
Measured: From UFNET initiation (T0) to 24 hours.
Net Ultrafiltration Rate (mL/kg/h)
Prescribed and achieved net ultrafiltration rate during continuous renal replacement therapy.
Measured: From UFNET initiation (T0) to 24 hours.
Time to First Ultrafiltration Intolerance Event (hours)
Time from UFNET initiation to the first occurrence of ultrafiltration intolerance.
Measured: From UFNET initiation to 24 hours.
Severity Category of Ultrafiltration Intolerance
Proportion of participants classified as having mild, moderate, or severe ultrafiltration intolerance according to protocol-defined criteria. Higher categories indicate greater severity of intolerance.
Measured: From UFNET initiation to 24 hours.
Agreement Between Hypotension-Based and Hypoperfusion-Based Definitions of Ultrafiltration Intolerance
Agreement between intolerance defined by hypotension criteria and intolerance defined by tissue hypoperfusion criteria, assessed using Cohen's kappa coefficient.
Measured: From UFNET initiation to 24 hours.
Cumulative Fluid Balance (mL)
Cumulative fluid balance achieved during the first 24 hours following UFNET initiation.
Measured: 24 hours after UFNET initiation
Achieved Net Ultrafiltration Volume (mL)
Total net ultrafiltration volume achieved during the observation period.
Measured: 24 hours after UFNET initiation
Proportion of Participants Achieving Renal Recovery
Percentage of participants who recover kidney function sufficiently to discontinue kidney replacement therapy according to the treating clinical team.
Measured: Up to 90 days after UFNET initiation
Ventilator-Free Days
Number of days alive and free from invasive mechanical ventilation.
Measured: Up to 28 days after UFNET initiation
Intensive Care Unit Mortality
Percentage of participants who die during intensive care unit admission.
Measured: From UFNET initiation up to 90 days or ICU discharge, whichever occurs first
Hospital Mortality
Percentage of participants who die during hospital admission.
Measured: From UFNET initiation until hospital discharge, assessed up to 180 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Jun 2026
- Study start6 Jul 2026
- Primary completion1 Dec 2027 (estimated)
- Study completion1 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (11)Papers the sponsor has linked to this study.
- Other trials for Acute Kidney InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 128 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospital Las Higueras
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Gonzalo Ramirez Guerrero, Hospital Las Higueras
- Investigators
- Gonzalo Ramírez-Guerrero, MD, Principal investigator, Hospital Las Higueras de Talcahuano
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07643597
- Sponsor's protocol ID
- CEC-SST-15-2026
- Acronym
- VINKO
- Status last verified
- Jul 2026
- First submitted
- 1 Jun 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: The investigators have not yet determined whether individual participant data (IPD) will be shared. Any future decision regarding data sharing will be made in accordance with institutional policies, ethical approvals, participant confidentiality requirements, and applicable regulations.
Publications
Ruste M, Delas Q, Fellahi JL, Jacquet-Lagreze M. Perfusion variables and hemodynamic phenotypes during fluid removal via net ultrafiltration in continuous renal replacement therapy: a retrospective single-center cohort study. J Crit Care. 2026 Feb;91:155310. doi: 10.1016/j.jcrc.2025.155310. Epub 2025 Oct 15.
PubMed 41101138Bige N, Lavillegrand JR, Dang J, Attias P, Deryckere S, Joffre J, Dubee V, Preda G, Dumas G, Hariri G, Pichereau C, Baudel JL, Guidet B, Maury E, Boelle PY, Ait-Oufella H. Bedside prediction of intradialytic hemodynamic instability in critically ill patients: the SOCRATE study. Ann Intensive Care. 2020 Apr 22;10(1):47. doi: 10.1186/s13613-020-00663-x.
PubMed 32323060Wong A, Olusanya O, Watchorn J, Bramham K, Hutchings S. Utility of the Venous Excess Ultrasound (VEXUS) score to track dynamic change in volume status in patients undergoing fluid removal during haemodialysis - the ACUVEX study. Ultrasound J. 2024 Mar 27;16(1):23. doi: 10.1186/s13089-024-00370-9.
PubMed 38538806da Hora Passos R, Caldas JR, Ramos JGR, Dos Santos Galvao de Melo EB, Silveira MAD, Batista PBP. Prediction of hemodynamic tolerance of intermittent hemodialysis in critically ill patients: a cohort study. Sci Rep. 2021 Dec 8;11(1):23610. doi: 10.1038/s41598-021-03110-4.
PubMed 34880359Douvris A, Zeid K, Hiremath S, Bagshaw SM, Wald R, Beaubien-Souligny W, Kong J, Ronco C, Clark EG. Mechanisms for hemodynamic instability related to renal replacement therapy: a narrative review. Intensive Care Med. 2019 Oct;45(10):1333-1346. doi: 10.1007/s00134-019-05707-w. Epub 2019 Aug 12.
PubMed 31407042Ruste M, Sghaier R, Chesnel D, Didier L, Fellahi JL, Jacquet-Lagreze M. Perfusion-based deresuscitation during continuous renal replacement therapy: A before-after pilot study (The early dry Cohort). J Crit Care. 2022 Dec;72:154169. doi: 10.1016/j.jcrc.2022.154169. Epub 2022 Oct 3.
PubMed 36201978Bitker L, Dupuis C, Pradat P, Deniel G, Klouche K, Mezidi M, Chauvelot L, Yonis H, Baboi L, Illinger J, Souweine B, Richard JC. Fluid balance neutralization secured by hemodynamic monitoring versus protocolized standard of care in patients with acute circulatory failure requiring continuous renal replacement therapy: results of the GO NEUTRAL randomized controlled trial. Intensive Care Med. 2024 Dec;50(12):2061-2072. doi: 10.1007/s00134-024-07676-1. Epub 2024 Oct 17.
PubMed 39417870Ramirez-Guerrero G, Ronco C, Rosner M. Ultrafiltration Tolerance and Improving Outcomes with Continuous Renal Replacement Therapies. Clin J Am Soc Nephrol. 2025 Mar 1;20(3):462-464. doi: 10.2215/CJN.0000000650. Epub 2024 Dec 26. No abstract available.
PubMed 39724028Ramirez-Guerrero G, Ronco C. Ultrafiltration Tolerance: A Phenotype That We Need to Recognize. Blood Purif. 2024;53(7):541-547. doi: 10.1159/000537941. Epub 2024 Feb 20.
PubMed 38377967Melo P, Ramirez-Guerrero G, Castro R, Wong A, Argaiz ER, Ostermann M, Hernandez G, Kattan E. Ultrafiltration in the critically ill patient: a framework for personalized care. Crit Care. 2026 Jan 24;30(1):87. doi: 10.1186/s13054-026-05836-x.
PubMed 41580864Ramirez-Guerrero G, Pedreros-Rosales C, Galindo P, Ulloa R, Alarcon J, Avila S, Kattan E, Melo P, Ballesteros D, Valenzuela R, Guimaraes G, Ferrada R, Pfeifer C, Villalobos V, Mas G, Marcello M, Klinkmann G, Ronco C. Volume removal intolerance during net ultrafiltration in patients with acute kidney injury in the intensive care unit: protocol for a prospective multicentre observational study (VINKO). BMJ Open. 2026 Sep 15;16(9):e125067. doi: 10.1136/bmjopen-2026-125067.
PubMed 42744368